Explore a rare case of systemic mastocytosis in a young adult, highlighting its role in unexplained osteoporosis and the need ...

A new case report was published in Oncoscience's Volume 12 on February 4, 2025, titled “Breaking point: Systemic mastocytosis manifesting as severe osteoporosis.” ...

The biopsies were examined by electron and confocal microscopy for HRP and CRH receptor localisation, respectively. Moreover, CRH receptor mRNA and protein expression were examined in the human mast ...

At this time, I would like to welcome everyone to the Blueprint Medicines 4Q and FY 2024 earnings release and conference call. Thank you, Nadia. Good morning, everyone, and welcome to Blueprint ...

This report highlights the diagnostic challenges of SM, emphasize its underrecognized role in osteoporosis and fragility fractures, and advocates for ...

Blueprint Medicines Corporation, a Delaware-based biopharmaceutical company, recently released its financial results for the year ended December 31, 2024, along with key business highlights. The ...

Reports Q4 revenue $144.1M, consensus $145.18M. “We are entering 2025 in the strongest position we have ever been in as a company with a focus ...

Q4 2024 Earnings Call Transcript February 13, 2025 Blueprint Medicines Corporation misses on earnings expectations. Reported ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

JMP Securities reiterated their market outperform rating on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a ...

Third Harmonic Bio, Inc. (NASDAQ:THRD) revealed results from its Phase 1 single and multiple ascending dose (SAD/MAD) trial ...

Blueprint Medicines Corporation ( NASDAQ: BPMC) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ET ...